Pasar al contenido principal

Featured Research Studies

We believe that one of the most effective ways to improve the lives of people with lupus is through research. Research holds the keys to discovering what causes lupus, to creating better treatments, and ultimately, to finding a cure.

There are more than 50 clinical trials for lupus. All of these studies depend on volunteers to make discoveries and find new treatments.

Scientists are studying more new treatments than ever before. If you want to get involved, we explain how clinical trials work and give you the information you need every step of the way.

Featured Research Studies

The IM014-029 Study is a research study evaluating an oral investigational drug to see if it may reduce symptoms of active lupus. If you have been diagnosed with active lupus for 6 months or more, you may qualify to take part in this study.


The purpose of this study is to assess if the investigational study medication dapirolizumab pegol (DZP), used in addition to your current systemic lupus erythematosus (SLE) medication, may improve your SLE.

Violet Study

A clinical research study evaluating an investigational drug, efavaleukin alfa, in people with lupus who have continued disease activity despite current therapy.

New study enrolling patients with active Systemic Lupus Erythematosus (SLE)

A Phase 2b Dose Ranging Study to Evaluate the Efficacy and Safety of Rozibafusp alfa (AMG 570) in Subjects with Active Systemic Lupus Erythematosus (SLE) With Inadequate Response to Standard of Care (SOC) Therapy


The purpose of this study is to evaluate the safety and effectiveness of an investigational medication, in people with systemic lupus erythematosus (SLE), also known as lupus.

Lupus Nephritis (LN) Clinical Trial Now Evaluating Potential New Treatment

The purpose of this study is to evaluate whether secukinumab works and is safe in lupus patients with active Lupus Nephritis (kidney disease associated with lupus) when with current standard of care.

Participants Needed for a Study Evaluating a New Treatment for Skin/Cutaneous Lupus

A randomized, double-blind, placebo controlled, proof of concept study assessing the efficacy and safety of the RIPK1-inhibitor SAR443122 in patients with moderate to severe subacute cutaneous lupus erythematosus (SCLE) or discoid/chronic cutaneous lupus erythematosus (DLE). SCLE and DLE are two types of lupus that affect the skin.

Enroll in Patient-Powered Research

RAY: Research Accelerated by You is a lupus data platform where people with lupus and caregiversprovide information about their lupus experience. Help brighten the future of lupus research.

Find Out More